Damora Therapeutics (DMRA) Common Equity (2019 - 2026)

Damora Therapeutics has reported Common Equity for 8 years, with the latest figure at $511.6 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 3631.88% year-over-year to $511.6 million; the trailing twelve-month figure through Mar 2026 stood at $511.6 million (up 3631.88% YoY), and the FY2025 full-year result was $240.4 million, up 1418.41% from the prior year.
• Common Equity for Q1 2026 stood at $511.6 million, up from $240.4 million in the prior quarter.
• The five-year high for Common Equity was $511.6 million in Q1 2026, with the low at $8.0 million in Q3 2025.
• Historically, Common Equity has averaged $79.9 million across 5 years, with a median of $37.4 million in 2023.
• Annual changes were most pronounced in 2025 — Common Equity sank 61.75% — and 2026, when it surged 3631.88%.
• Damora Therapeutics' Common Equity stood at $61.8 million in 2022, then tumbled by 47.64% to $32.3 million in 2023, then plunged by 51.03% to $15.8 million in 2024, then jumped by 1418.41% to $240.4 million in 2025, then jumped by 112.83% to $511.6 million in 2026.
• The last three Common Equity figures came in at $511.6 million (Q1 2026), $240.4 million (Q4 2025), and $8.0 million (Q3 2025), per Business Quant data.